Strs Ohio Has $624,000 Stake in Tarsus Pharmaceuticals, Inc. $TARS

Strs Ohio reduced its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 43.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,500 shares of the company’s stock after selling 8,000 shares during the period. Strs Ohio’s holdings in Tarsus Pharmaceuticals were worth $624,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in Tarsus Pharmaceuticals by 77.0% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 91,590 shares of the company’s stock valued at $5,443,000 after acquiring an additional 39,838 shares in the last quarter. Campbell & CO Investment Adviser LLC raised its stake in Tarsus Pharmaceuticals by 48.6% in the third quarter. Campbell & CO Investment Adviser LLC now owns 15,261 shares of the company’s stock valued at $907,000 after purchasing an additional 4,988 shares in the last quarter. West Wealth Group LLC acquired a new position in Tarsus Pharmaceuticals in the third quarter valued at about $202,000. Capricorn Fund Managers Ltd bought a new stake in Tarsus Pharmaceuticals during the third quarter worth about $14,264,000. Finally, Assenagon Asset Management S.A. grew its stake in Tarsus Pharmaceuticals by 25.1% during the third quarter. Assenagon Asset Management S.A. now owns 1,247,954 shares of the company’s stock worth $74,166,000 after buying an additional 250,367 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on TARS shares. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. HC Wainwright lifted their price objective on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a research note on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Guggenheim raised their target price on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $51.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $79.86.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 7,397 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the transaction, the insider directly owned 38,958 shares in the company, valued at approximately $3,120,535.80. This trade represents a 15.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the sale, the chief executive officer directly owned 857,991 shares in the company, valued at $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 8.97% of the stock is owned by corporate insiders.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $65.71 on Friday. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. The company has a market cap of $2.79 billion, a price-to-earnings ratio of -32.53, a PEG ratio of 0.93 and a beta of 0.59. The firm has a 50 day simple moving average of $77.84 and a 200 day simple moving average of $65.11.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. The company had revenue of $118.70 million during the quarter, compared to the consensus estimate of $114.22 million. Research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.